Related references
Note: Only part of the references are listed.Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
Phil Pickford et al.
MOLECULAR METABOLISM (2021)
Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1
Amaara Marzook et al.
BIOCHEMICAL PHARMACOLOGY (2021)
New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling
Alejandra Tomas et al.
JOURNAL OF MOLECULAR BIOLOGY (2020)
Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide
Philip Pickford et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Disconnect between signalling potency and in vivo ef fi cacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
Maria Lucey et al.
MOLECULAR METABOLISM (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
Michael A. Nauck et al.
MOLECULAR METABOLISM (2020)
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Aaron Novikoff et al.
MOLECULAR METABOLISM (2020)
Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells
Zijian Fang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists
Zijian Fang et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells
Teresa Buenaventura et al.
PLOS BIOLOGY (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
Stephen T. Buckley et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists
Jacqueline Naylor et al.
BIOCHEMICAL JOURNAL (2016)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Hongkai Zhang et al.
NATURE COMMUNICATIONS (2015)
Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion
HE Hohmeier et al.
DIABETES (2000)
Share Paper
